Go or no go? Pdufa resolutions eyed for J&J and Amryt
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Esmo 2021 movers – a handful of biotech winners emerge
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Europe’s venture boom trails the US
But financing sizes have grown by a similar amount on both sides of the Atlantic.
The flotation window stays open, for now
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
Immatics takes up the Spac baton
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
